Hypericum-venlafaxine

From Psychiatrienet
Revision as of 15:33, 7 May 2009 by Alexandra (talk | contribs)
Jump to: navigation, search
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort
Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine

Switch medication from hypericum to mirtazapine.[1] [2]

Nietinrijdenbord.png Stop hypericum
  • Administration of hypericum can be stopped abruptly.
Eenrichtingbord.png Start mirtazapine
  • Day 1-7: a wash-out period of one week is necessary.
  • Day 8: start administration of venlafaxine in a dosage of 37,5 mg/day.
  • Day 15: increase dosage of venlafaxine to 75 mg/day.
  • If necessary, increase dosage of venlafaxine further.
Infobord.png More information
  • Occurrence of the serotonin syndrome is theoretically possible.
  • Hypericum slows the metabolism of venlafaxine via CYP3A4. This effect may persist up to two weeks after stopping hypericum, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.